298 related articles for article (PubMed ID: 33313998)
21. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
22. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.
Luger TA; Lahfa M; Fölster-Holst R; Gulliver WP; Allen R; Molloy S; Barbier N; Paul C; Bos JD
J Dermatolog Treat; 2004 Jun; 15(3):169-78. PubMed ID: 15204150
[TBL] [Abstract][Full Text] [Related]
23. [Diagnostic, prophylactic and therapeutic guidelines in patients with atopic dermatitis. Position paper by the task force of the National Specialists on Dermatology, Venereology and Allergology].
Gliński W; Kruszewski J; Silny W; Kurzawa R; Czarnecka-Operacz M; Baran E; Szepietowski J;
Pol Merkur Lekarski; 2004; 17 Suppl 3():3-15. PubMed ID: 15688665
[TBL] [Abstract][Full Text] [Related]
24. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas.
Draelos ZD
Curr Med Res Opin; 2008 Apr; 24(4):985-94. PubMed ID: 18284804
[TBL] [Abstract][Full Text] [Related]
25. Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis.
Chia BK; Tey HL
Dermatitis; 2015; 26(3):122-32. PubMed ID: 25984688
[TBL] [Abstract][Full Text] [Related]
26. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema.
Pitt M; Garside R; Stein K
Br J Dermatol; 2006 Jun; 154(6):1137-46. PubMed ID: 16704646
[TBL] [Abstract][Full Text] [Related]
27. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.
Frankel HC; Qureshi AA
Am J Clin Dermatol; 2012 Apr; 13(2):113-23. PubMed ID: 22263704
[TBL] [Abstract][Full Text] [Related]
28. The role of topical calcineurin inhibitors in atopic dermatitis.
Alomar A; Berth-Jones J; Bos JD; Giannetti A; Reitamo S; Ruzicka T; Stalder JF; Thestrup-Pedersen K;
Br J Dermatol; 2004 Dec; 151 Suppl 70 Dec 2004():3-27. PubMed ID: 15548171
[TBL] [Abstract][Full Text] [Related]
29. Evidence Review of Topical Calcineurin Inhibitors for the Treatment of Adult Atopic Dermatitis.
Hong CH; Gooderham M; Bissonnette R
J Cutan Med Surg; 2019; 23(4_suppl):5S-10S. PubMed ID: 31476937
[TBL] [Abstract][Full Text] [Related]
30. Atopic dermatitis - all you can do from the outside.
Gelmetti C; Wollenberg A
Br J Dermatol; 2014 Jul; 170 Suppl 1():19-24. PubMed ID: 24720530
[TBL] [Abstract][Full Text] [Related]
31. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial.
Gollnick H; Kaufmann R; Stough D; Heikkila H; Andriano K; Grinienko A; Jimenez P;
Br J Dermatol; 2008 May; 158(5):1083-93. PubMed ID: 18341665
[TBL] [Abstract][Full Text] [Related]
32. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
[TBL] [Abstract][Full Text] [Related]
33. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
[TBL] [Abstract][Full Text] [Related]
34. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.
Kapp A; Papp K; Bingham A; Fölster-Holst R; Ortonne JP; Potter PC; Gulliver W; Paul C; Molloy S; Barbier N; Thurston M; de Prost Y;
J Allergy Clin Immunol; 2002 Aug; 110(2):277-84. PubMed ID: 12170269
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials.
Abędź N; Pawliczak R
Postepy Dermatol Alergol; 2019 Dec; 36(6):752-759. PubMed ID: 31998006
[TBL] [Abstract][Full Text] [Related]
36. Effects of a protein-free oat plantlet extract on microinflammation and skin barrier function in atopic dermatitis patients.
Wollenberg A; Fölster-Holst R; Saint Aroman M; Sampogna F; Vestergaard C
J Eur Acad Dermatol Venereol; 2018 Apr; 32 Suppl 1():1-15. PubMed ID: 29533490
[TBL] [Abstract][Full Text] [Related]
37. An Open-Label Prospective Study to Compare the Efficacy and Safety of Topical Fluticasone Versus Tacrolimus in the Proactive Treatment of Atopic Dermatitis.
Mudaliyar VR; Pathak A; Dixit A; Kumar SS
Dermatol Pract Concept; 2020 Oct; 10(4):e2020094. PubMed ID: 33150035
[TBL] [Abstract][Full Text] [Related]
38. Association Between the Use of Topical Calcineurin Inhibitors and the Risk of Cancer Among Patients with Atopic Dermatitis: A Nationwide, Population-Based, Retrospective Cohort Study.
Huang HH; Shen D; Chan TC; Cho YT; Tang CH; Chu CY
Am J Clin Dermatol; 2023 Sep; 24(5):799-808. PubMed ID: 37280416
[TBL] [Abstract][Full Text] [Related]
39. Pimecrolimus: a review of its use in atopic dermatitis.
Wellington K; Noble S
Am J Clin Dermatol; 2004; 5(6):479-95. PubMed ID: 15663345
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
